L19-IL2 fusion protein

Drug Profile

L19-IL2 fusion protein

Alternative Names: Anti-EDB-IL2 antibody conjugate; Anti-EDB-interleukin-2 antibody conjugate; Darleukin; Immunocytokine therapy; L19 interleukin-2 fusion-protein; L19-IL-2

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Philogen
  • Developer Bayer Schering Pharma; Maastricht Radiation Oncology; Philogen
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase I/II Diffuse large B cell lymphoma; Pancreatic cancer
  • Phase I Head and neck cancer; Solid tumours
  • No development reported Renal cell carcinoma
  • Discontinued Atherosclerosis

Most Recent Events

  • 12 Oct 2017 The US FDA approves IND application for L19-IL2 in Malignant melanoma (Metastatic disease, Neoadjuvant therapy, Late-stage disease, Combination therapy)
  • 21 Jan 2016 Phase-III clinical trials in Malignant melanoma (Metastatic disease, Neoadjuvant therapy, Late-stage disease, Combination therapy) in Poland (IV) after January 2016 (EudraCT2015-002549-72)
  • 21 Jan 2016 Phase-III clinical trials in Malignant melanoma (Combination therapy, Metastatic disease) in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top